Structured evidence table for Prebiotic Xylooligosaccharides Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Prebiotic Xylooligosaccharides Gut Health Randomized Trial | It is a substrate selectively utilized by the host‐associated microorganisms conferring a health benefit. | 4 | Costa Paula Cavion (2026) | Advances in Xylooligosaccharides Production From Lignocellulosic Materials and Its Application as Prebiotics |
| Prebiotic Xylooligosaccharides Gut Health Randomized Trial | They increase calcium absorption, confer protection against cardiovascular diseases, increase nutrient absorption, inhibit pathogenic microorganisms, reduce the risk of colon cancer, promote an immunological response, have antioxidant capacity, as well as antiallergic and anti‐inflammatory effects. | 4 | Costa Paula Cavion (2026) | Advances in Xylooligosaccharides Production From Lignocellulosic Materials and Its Application as Prebiotics |
| Prebiotic Xylooligosaccharides Gut Health Randomized Trial | Accordingly, this review distinguishes itself by critically integrating recent advances in the enzymatic bioconversion of lignocellulosic biomass (LCB), precision strategies for controlling the structural features of XOS—including degree of polymerization (DP) and substitution patterns—and functional evidence from in vitro systems, animal models, and human clinical studies. | 4 | Costa Paula Cavion (2026) | Advances in Xylooligosaccharides Production From Lignocellulosic Materials and Its Application as Prebiotics |
| Prebiotic Xylooligosaccharides Gut Health Randomized Trial | α L ‐‐arabinofuranosidase α ‐glucuronidase 2017 2021 2023 2024 The concept of prebiotics has evolved over the years and has now reached a consensus. | 4 | Costa Paula Cavion (2026) | Advances in Xylooligosaccharides Production From Lignocellulosic Materials and Its Application as Prebiotics |
| Prebiotic Xylooligosaccharides Gut Health Randomized Trial | Bifidobacteria are common members of the human gut microbiota and are associated with host health. | 4 | Friess L (2026) | Genetic and enzymatic basis of xylooligosaccharide metabolism by <i>Bifidobacterium longum</i>. |
| Prebiotic Xylooligosaccharides Gut Health Randomized Trial | longum ) is prevalent across host ages and can utilise diverse plant-derived glycans, including xylooligosaccharides (XOS), that are indigestible by humans. | 4 | Friess L (2026) | Genetic and enzymatic basis of xylooligosaccharide metabolism by <i>Bifidobacterium longum</i>. |
Source documents